Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb 10;8(1):37-53.
doi: 10.5306/wjco.v8.i1.37.

From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis

Melissa Bersanelli  1 , Sebastiano Buti  1
Affiliations
Review

From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis

Melissa Bersanelli et al. World J Clin Oncol. .

Abstract

After that the era of chemotherapy in the treatment of solid tumors have been overcome by the "translational era", with the innovation introduced by targeted therapies, medical oncology is currently looking at the dawn of a new "immunotherapy era" with the advent of immune checkpoint inhibitors (CKI) antibodies. The onset of PD-1/PD-L1 targeted therapy has demonstrated the importance of this axis in the immune escape across almost all human cancers. The new CKI allowed to significantly prolong survival and to generate durable response, demonstrating remarkable efficacy in a wide range of cancer types. The aim of this article is to review the most up to date literature about the clinical effectiveness of CKI antibodies targeting PD-1/PD-L1 axis for the treatment of advanced solid tumors and to explore transversal challenges in the immune checkpoint blockade.

Keywords: Anti-PD-1 antibodies; Anti-PD-L1 antibodies; Cancer treatment; Checkpoint inhibitors; Immune checkpoint blockade; Immune checkpoint inhibitors; PD-1; PD-L1.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: No potential conflicts of interest. No financial support.

References

    1. Lee CS, Cragg M, Glennie M, Johnson P. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol. 2013;76:233–247. - PMC - PubMed
    1. Naing A, Gelderblom H, Gainor J, Forde PM, Butler M, Lin CC, Sharma S, Ochoa de Olza M, Schellens JHM, Soria JC, et al. A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors. 2016 ASCO Annual Meeting, Poster Discussion. J Clin Oncol. 2016;34 Suppl:abstr 3060.
    1. Eli Lilly and Company. A study of anti-PD-L1 checkpoint antibody (LY3300054) alone and in combination in participants with advanced refractory solid tumors (PACT). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: https://clinicaltrials.gov/ct2/show/NCT02791334.
    1. Bristol-Myers Squibb. Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: https://clinicaltrials.gov/ct2/show/NCT02534506.
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. - PMC - PubMed